Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1916 Jan 1;23(1):61–68. doi: 10.1084/jem.23.1.61

ANTIBLASTIC IMMUNITY

A R Dochez 1, O T Avery 1
PMCID: PMC2125341  PMID: 19867971

Abstract

1. Antipneumococcus serum possesses the power of inhibiting for a certain period of time the multiplication of pneumococci. 2. It also has the capacity of inhibiting the proteolytic and glycolytc functions of pneumococci. 3. This power is acquired for the first time or appears in increased amounts in human serum at the time of crisis in lobar pneumonia. 4. The retardation of bacterial growth is thought to be dependent upon the inhibition of metabolic function due to the presence of anti-enzymotic substances in antipneumococcus serum. To this phenomenon we have applied the term antiblastic immunity.

Full Text

The Full Text of this article is available as a PDF (385.3 KB).


Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES